Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy and safety of CP-945,598 in obese subjects
2006-005084-26Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing CP-945,598 with Placebo (2 arms). Primary endpoints: Long-term efficacy (co-primary endpoints) and Long-term safety. Started Dec 2006; status: terminated.
02
Drugs
otenabant
03
Conditions
obesity
Beyond the preview
Go deeper on 2006-005084-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005084-26.